• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Nanobiotix S.A.

    5/14/25 6:00:07 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    6-K 1 f6k_051325.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-39777

    Nanobiotix S.A.
    (Translation of registrant's name into English)

    60 Rue de Wattignies 75012 Paris, France
    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

     

     


    On May 14, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    (c) Exhibit 99.1. Press release dated May 14, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Nanobiotix S.A.    
      (Registrant)
       
      
    Date: May 14, 2025     /s/ Bart Van Rhijn    
      Bart Van Rhijn
      Chief Financial Officer
      
    Get the next $NBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings